- Sanofi
- 24 December 2025 07:46:53
Source: Sharecast
Dynavax’s adult hepatitis B vaccine is currently marketed in the US, while its shingles vaccine candidate is in phase 1/2 clinical development.
The company said the acquisition augments its presence in adult immunisation by bringing together Dynavax’s vaccines with Sanofi’s "global scale, development capabilities and commercial reach".
Under the terms of the deal, Sanofi will start a cash tender offer to buy all outstanding shares of Dynavax for $15.50 per share.
Thomas Triomphe, executive vice president of vaccines at Sanofi, said: "Dynavax enhances Sanofi’s adult immunisation presence by adding differentiated vaccines that complement Sanofi’s expertise.
"Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan."
The acquisition, which is due to close in the first quarter of next year, is not expected to have any impact on Sanofi's financial guidance for 2025.